Tight junction proteins in keratinocytes: localization and contribution to barrier function

Tobisawa, Yuki; Haratake, Akinori; Koishikawa, Hisa; Morita, Kazumasa; Miyachi, Yoshiki; Inoue, Shintaro

doi:10.1111/j.1600-0625.2006.00539.x

Cited by 103 publications

(128 citation statements)

References 31 publications

Supporting

Mentioning

120

Contrasting

Unclassified

Order By: Relevance

“…Concerning the exact localization of the functional TJ barrier, it has been suggested that it is localized in human and murine skin in the mid layers of the SG 3,11,21 ; although other studies have found TJ barrier to be at the uppermost layer of the SG. 15 Using cultured keratinocytes, it was shown that, TJs form a barrier to water 24 and molecules of different size ( [24][25][26][27][28] ) as well as ions (e.g. Na C , Cl ¡ , Ca 2C ).…”

Section: Tj Composition and Function In Healthy Skin (And Cultured Kementioning

confidence: 99%

Epidermal tight junctions in health and disease

et al. 2014

View full text Add to dashboard Cite

Section: Tj Composition and Function In Healthy Skin (And Cultured Kementioning

confidence: 99%

Epidermal tight junctions in health and disease

et al. 2014

View full text Add to dashboard Cite

“…Then transepithelial electric resistance (TER) was measured using a Millicell-ERS epithelial voltmeter (Millipore), as described in a previous study (6). TER by the keratinocyte sheet gives an indication of the transepithelial permeability of water-soluble ions.…”

Section: Transfection Of Keratinocytes With Myd88 Small Interfering Rnamentioning

confidence: 99%

“…In the murine epidermis, typical stratified epithelia, TJ structures are restricted to the stratum granulosum, where continuous TJs, including occludin, claudin-1, and claudin-4, were identified by immunofluorescence microscopy analyses (3,4). Furthermore, TJs function as paracellular barriers against small molecules in the human epidermis and cultured keratinocytes (5,6). However, the exact role of TJs in cutaneous barriers remains unclear in relation to that of the stratum corneum.…”

mentioning

confidence: 99%

Activation of TLR2 Enhances Tight Junction Barrier in Epidermal Keratinocytes

Tobisawa¹,

Yoshida²,

Akazawa³

et al. 2011

The Journal of Immunology

Self Cite

114

View full text Add to dashboard Cite

The epidermis has developed physical and immunological barriers that prevent infiltration of deleterious chemicals and pathogens. As a first step to understanding the relationship between these barriers, we investigated whether TLR2 activation functionally alters tight junctions (TJs) in cultured human keratinocytes. Stimulation with peptidoglycan, a ligand for TLR2, elevated the TJ-associated barrier in the space of 3 h. The increase in TJ-associated barrier function due to peptidoglycan stimulation was suppressed by the knockdown of TLR adaptor MyD88 or the pretreatment with TLR2-neutralizing Ab, indicating that TLR2 activation enhanced TJ-associated barrier. One and 3 h after peptidoglycan stimulation, expression levels of the TJ proteins occludin, claudin-1, claudin-4, and ZO-1 were unchanged. However, immunoprecipitation studies demonstrated that the association of phospho-atypical protein kinase Cζ/ι, crucial for TJ biogenesis, with occludin was increased. Significantly, inhibition of atypical protein kinase Cζ/ι activity completely blocked the immediate elevation of the TJ-associated barrier. Finally, peptidoglycan was applied to the stratum corneum surface of a human skin equivalent, and the TJ barrier was evaluated. In the space of 3 h after the stimulation, the amount of intercellular tracer in the stratum corneum incubated from the dermal side was reduced, indicating that the TJ barrier is strengthened via TLR2 activation. Taken together, our findings indicated that infiltration of pathogens into the epidermis immediately enhanced TJ function via TLR2 signaling. Furthermore, the dynamically controlled TJs in skin are considered fundamental in preventing further invasion of pathogens and maintaining cutaneous barrier homeostasis.

show abstract

“…Claudin-1 and claudin-4 in particular have been shown to be critical for the function of tight junctions [7].…”

Section: Introductionmentioning

confidence: 99%

Overexpression of Claudin-1 is Associated with Advanced Clinical Stage and Invasive Pathologic Characteristics of Oral Squamous Cell Carcinoma

Sappayatosok

Phattarataratip

2014

Head and Neck Pathol

View full text Add to dashboard Cite

Claudins constitute a group of principal proteins forming the tight junctional complex. The altered expression of selected claudins has been reported in several human cancers. The purpose of this study was to investigate the expression of claudin-1 and claudin-4 in oral squamous cell carcinoma (OSCC) and examine its relationship with patient clinical-pathologic features. Fortyfive OSCC cases were enrolled. Patient clinical, pathologic and follow-up data were reviewed and the claudin-1 and claudin-4 expression was analyzed immunohistochemically. Positive claudin-1 and claudin-4 immunoreactivities were noted in 86.7 and 80 % of cases, respectively. The majority of cases showed the staining in less than 25 % of cancer cells. The increased claudin-1 expression was significantly associated with the high pathologic grade, the presence of microscopic perineural invasion, vascular invasion, nodal metastasis, and advanced clinical stage. No relationship between various clinico-pathologic parameters and differential claudin-4 expression was observed.Claudin-1 may play a role in OSCC progression and could serve as a prognostic marker of advanced disease.

show abstract

Tight junction proteins in keratinocytes: localization and contribution to barrier function

Cited by 103 publications

References 31 publications

Epidermal tight junctions in health and disease

Epidermal tight junctions in health and disease

Activation of TLR2 Enhances Tight Junction Barrier in Epidermal Keratinocytes

Overexpression of Claudin-1 is Associated with Advanced Clinical Stage and Invasive Pathologic Characteristics of Oral Squamous Cell Carcinoma

Contact Info

Product

Resources

About